1. Protocols for Weaning Intensive Therapies

Structured tapering of vasoactive infusions and high-dose insulin is critical to prevent rebound hypotension or bradycardia while minimizing metabolic and hemodynamic complications.

1.1 Criteria for Vasoactive Infusion Reduction and Cessation

• Hemodynamic targets sustained for ≥ 4 hours:
  • Mean Arterial Pressure (MAP) ≥ 65 mm Hg without escalating doses
  • Heart rate within patient’s baseline range
  • Serum lactate ≤ 2 mmol/L and trending down
• Volume status: Euvolemia confirmed by clinical exam and Point-of-Care Ultrasound (POCUS).
• Order of taper: Generally, catecholamines (e.g., epinephrine) are weaned first, followed by norepinephrine, with vasopressin weaned last.
• Taper increments: Reduce by 5–10% of the current rate every 1–2 hours if hemodynamic targets are maintained.

1.2 High-Dose Insulin Tapering Schedules and Monitoring

• Initiate taper when combined vasopressor support is low (e.g., ≤ 0.05 µg/kg/min norepinephrine equivalent).
• For insulin infusions below 2 U/kg/h, decrease by approximately 0.5 U/kg/h every 2–4 hours.
• Monitoring during taper is critical:
  • Blood glucose every 30 minutes (target 100–200 mg/dL)
  • Serum potassium every 2–4 hours (maintain 4.0–4.5 mEq/L)
  • Point-of-care lactate and bedside echo to ensure adequate perfusion

1.3 Monitoring for Rebound Hypotension or Bradycardia

• Utilize continuous arterial line and ECG monitoring throughout the weaning process.
• Criteria to pause taper and reassess:
  • MAP drop > 10 mm Hg below the patient’s stable baseline
  • New-onset bradycardia (HR < 50 bpm) accompanied by signs of hypoperfusion
  • Serum lactate rise > 1 mmol/L from its lowest point (nadir)
• If criteria are met, return to the prior effective infusion rate, reassess volume status, and correct any electrolyte abnormalities before re-attempting the wean.

2. Conversion to Enteral Therapies

Transitioning to oral regimens requires careful selection of agents with reliable bioavailability, consideration of appropriate enteral access, and understanding of dose-equivalence calculations.

2.1 Selection of Oral Agents: Bioavailability and Onset Considerations

• Midodrine: A prodrug converted to the active metabolite desglymidodrine. It has excellent bioavailability (75–100%) and a rapid onset of 30 minutes. Typical dosing is 5–10 mg three times daily.
• Fludrocortisone: A synthetic mineralocorticoid that supports vascular tone by promoting sodium and water retention. It has a slower onset of 1–2 days. Typical dosing is 0.1–0.2 mg daily.
• Oral Phenylephrine: Not recommended due to very low and erratic bioavailability.

2.2 Enteral Access Devices: NGT vs PEG in Prolonged ICU Stays

2.3 Dosing Equivalence and Absorption Caveats

• Parenteral-to-oral conversion: These are rough estimates and require clinical titration. For example, midodrine 10 mg orally may be roughly equivalent to 0.1 µg/kg/min of norepinephrine.
• Absorption factors: Always account for potential delays from first-pass metabolism and altered gastric motility in critically ill patients.
• Verification: Do not rely on serum levels. Verify adequate absorption and effect by monitoring clinical endpoints like MAP and heart rate.

3. Mitigating Post-ICU Syndrome (PICS)

Early implementation of the ABCDEF bundle and engagement of a multidisciplinary rehabilitation team are proven strategies to reduce long-term cognitive, psychological, and physical impairments.

3.1 ABCDEF Bundle Implementation

The ABCDEF bundle is a cornerstone of modern ICU care, designed to improve patient outcomes and reduce the incidence of PICS.

3.2 Rehabilitation Strategies: Physical, Cognitive, Nutritional

• Physical: Begin passive range-of-motion exercises on day 1. Progress to sitting at the edge of the bed, standing, and ambulating by days 3–5, as tolerated.
• Cognitive: Use orientation boards with the date and location, engage in reality reorientation, and introduce brief memory tasks to stimulate cognitive function.
• Nutritional: Provide high-protein enteral feeds (1.5–2 g/kg/day) to prevent muscle wasting. Consult a dietician early to address malnutrition.

3.3 Psychological Support and Early Mental Health Referral

• Screen for anxiety, depression, and PTSD at ICU discharge using validated tools (e.g., Hospital Anxiety and Depression Scale, IES-R).
• Provide bedside psychology consults for patients and families. Schedule outpatient behavioral health follow-up before discharge.
• Encourage family presence and involvement to help normalize sleep–wake cycles and reduce patient distress.

4. Medication Reconciliation and Discharge Planning

A structured reconciliation of antidotes, chronic therapies, and potential interactions is essential for a safe handoff and to prevent readmission.

4.1 Comprehensive Review of Medications

• Acute Therapies: Create a definitive list of all acute therapies received, such as calcium salts, glucagon, HIET, and lipid emulsion, for the discharge summary.
• Chronic Medications: Carefully reconcile home medications, paying close attention to those that may have contributed to the initial event (e.g., antihypertensives, antidepressants, hypoglycemics).
• Interactions: Screen for new drug-drug interactions, especially with medications started in the hospital (e.g., fludrocortisone can affect warfarin efficacy).

4.2 Patient and Caregiver Education

• Teach-Back Method: Use the teach-back method to confirm that the patient and caregivers understand medication changes, dosing schedules, and key side effects to monitor.
• Low-Literacy Materials: Provide simplified materials, such as pictograms for dosing schedules, large-print instructions, and a 24-hour helpline number for questions.

4.3 Coordination with Outpatient Teams

• Schedule follow-up appointments with primary care, cardiology, and psychiatry within 7 days of discharge.
• Send a comprehensive discharge summary to all outpatient providers, clearly outlining the overdose event, treatments rendered, and warning signs for relapse or complications.
• Engage case management or social work to connect the patient with social support systems and ensure access to outpatient mental health resources.

5. Outpatient Follow-Up and Quality Metrics

Long-term recovery requires regular monitoring of organ function, evaluation of medication adherence, and system-level quality improvement initiatives.

5.1 Laboratory and Echocardiographic Monitoring Schedules

• Labs: Check electrolytes, renal function, and liver function at 1 week and 1 month post-discharge, then quarterly as needed.
• Echocardiogram: Obtain a baseline echocardiogram before discharge. If LV dysfunction was present, repeat at 3 months and 12 months to monitor for recovery.

5.2 Tracking Adherence and Recurrence

• Monitor prescription refill histories, use pill counts, and consider plasma drug levels where appropriate and available.
• Actively screen for substance use relapse and coordinate care with addiction medicine specialists.

5.3 System-Level Quality Improvement Initiatives

• Track 30- and 90-day readmission rates for both overdose-related issues and heart failure exacerbations.
• Implement structured debriefs after each complex case to identify opportunities for refining weaning, discharge, and follow-up protocols.